Frank Litvack - 21 Feb 2023 Form 4 Insider Report for CAPRICOR THERAPEUTICS, INC. (CAPR)

Role
Director
Signature
/s/ Linda Marban, Attorney-in-Fact
Issuer symbol
CAPR
Transactions as of
21 Feb 2023
Net transactions value
-$0.91
Form type
4
Filing time
23 Feb 2023, 08:00:12 UTC
Previous filing
05 Jan 2023
Next filing
16 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAPR Common Stock Options Exercise $19,498 +14,027 +11% $1.39 141,800 21 Feb 2023 Direct
transaction CAPR Common Stock Tax liability $19,498 -4,524 -3.2% $4.31 137,276 21 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -14,027 -100% $0.000000* 0 21 Feb 2023 Common Stock 14,027 $1.39 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms.
F2 This option was granted on February 22, 2013 and was previously reported as covering 140,270 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F3 25% of the shares vested immediately, with the remainder vesting monthly over 25 months commencing May 1, 2013.